Spinogenix will soon launch a Phase 1/2 clinical trial in the U.S. to test its investigational small molecule SPG302 in people with amyotrophic lateral sclerosis (ALS). The trial, which will assess the medication’s safety, tolerability, and pharmacological properties when given as a once-daily pill, comes after The U.S.
News
The ALS Association has selected InnoVision Marketing Group as its agency of record for creating media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS) and the association’s mission of improving the lives of people with ALS. InnoVision, which has previously collaborated with the nonprofit on specific initiatives…
Clene Nanomedicine has nearly doubled the enrollment cap for a soon-to-launch expanded access program (EAP) to allow more patients to receive CNM-Au8 — its investigational treatment for amyotrophic lateral sclerosis (ALS) — outside of clinical trials. Also known as a compassionate use program, the EAP will…
The European Commission has approved Qalsody (tofersen) as a treatment for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene, known as SOD1-ALS. Qalsody was specifically granted marketing authorization under exceptional circumstances — a pathway recommended when the benefit-to-risk assessment for a therapy is favorable, but…
The Foundation for the National Institutes of Health (FNIH) is launching a public-private partnership to generate the largest openly available data platform in amyotrophic lateral sclerosis (ALS) research, with the goal of accelerating the diagnosis and treatment of the progressive neurodegenerative disease. This five-year initiative will be conducted through…
The Les Turner ALS Foundation, in an effort to boost and diversify clinical trial participation, has written a step-by-step guide to inform people on why clinical research in amyotrophic lateral sclerosis (ALS) needs a diverse pool of participants, how to join clinical research, and what to expect when…
The fourth annual Major League Baseball (MLB) Lou Gehrig Day takes place on June 2, a date set aside to pay tribute to the legendary New York Yankees first baseman whose career was halted by amyotrophic lateral sclerosis (ALS). The Muscular Dystrophy Association (MDA) will again play…
A new documentary about I AM ALS and the “revolutionary movement” begun by the organization’s founders — which will stream globally on May 28 — is seeking to advance awareness of amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders while inspiring others to fight for change. Called “For…
People with amyotrophic lateral sclerosis (ALS) who continued treatment with NurOwn (debamestrocel) after completing a Phase 3 trial experienced additional benefits with extended treatment, data show. The findings come from 10 adults who received up to six additional doses of NurOwn over nearly one year in an expanded…
By taking advantage of a molecular interaction between the disease-related protein TDP-43 and another, innocuous protein, scientists have found a novel strategy that potentially may be used as a treatment for amyotrophic lateral sclerosis (ALS). “Importantly, this interaction could be key to unlocking a treatment not just for ALS…
Recent Posts
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002